Hypernatremia in Hospitalized Patients: A Large Population-Based Study

Soraya Arzhan 1, Maria-Eleni Roumelioti, Igor Litvinovich, Cristian G. Bologa 2, Orrin B. Myers 3, and Mark L. Unruh 1,4

Key Points
- Hypernatremia has been studied less than hyponatremia and may serve as an important predictor of outcomes among hospitalized patients.
- This work addresses a key gap regarding outcomes of hypernatremia by assessing the relationship of hypernatremia to outcomes by eGFR or age groups.
- Hypernatremia was significantly associated with in-hospital mortality and discharge to a hospice or nursing facility.

Abstract
Background Hypernatremia is a frequently encountered electrolyte disorder in hospitalized patients. Controversies still exist over the relationship between hypernatremia and its outcomes in hospitalized patients. This study examines the relationship of hypernatremia to outcomes among hospitalized patients and the extent to which this relationship varies by kidney function and age.

Methods We conducted an observational study to investigate the association between hypernatremia, eGFR, and age at hospital admission and in-hospital mortality, and discharge dispositions. We analyzed the data of 1.9 million patients extracted from the Cerner Health Facts databases (2000–2018). Adjusted multinomial regression models were used to estimate the relationship of hypernatremia to outcomes of hospitalized patients.

Results Of all hospitalized patients, 3% had serum sodium (Na) >145 mEq/L at hospital admission. Incidence of in-hospital mortality was 12% and 2% in hyper- and normonatremic patients, respectively. The risk of all outcomes increased significantly for Na >155 mEq/L compared with the reference interval of Na = 135–145 mEq/L. Odds ratios (95% confidence intervals) for in-hospital mortality and discharge to a hospice or nursing facility were 34.41 (30.59–38.71), 21.14 (17.53–25.5), and 12.21 (10.95–13.61), respectively (all P<0.001). In adjusted models, we found that the association between Na and disposition was modified by eGFR (P<0.001) and by age (P<0.001). Sensitivity analyses were performed using the eGFR equation without race as a covariate, and the inferences did not substantially change. In all hypernatremic groups, patients aged 76–89 and ≥90 had higher odds of in-hospital mortality compared with younger patients (all P<0.001).

Conclusions Hypernatremia was significantly associated with in-hospital mortality and discharge to a hospice or nursing facility. The risk of in-hospital mortality and other outcomes was highest among those with Na >155 mEq/L. This work demonstrates that hypernatremia is an important factor related to discharge disposition and supports the need to study whether protocolized treatment of hypernatremia improves outcomes.

Introduction
Compared with hyponatremia, hypernatremia among hospitalized patients is a less prevalent electrolyte disorder (1–3) and its outcomes have been less studied (1). The prevalence of hypernatremia among hospitalized patients has been reported as being between 1% and 4% (1,2,4–7).

Although some studies have shown an increase in mortality in older patients with hypernatremia (8–10), others have not demonstrated this association (1,11). There have also been limitations in selecting the clinical setting, such as inpatient or outpatient (1,9,12), which has led to variations in the prevalence of hypernatremia (13–15). Additionally, little is known about
the association between hypernatremia and discharge dispositions—specifically, discharge to a hospice or nursing facility in hospitalized patients (1). These discharge dispositions are key patient-centered outcomes. Moreover, most of the studies addressing the relationship between hypernatremia and selected outcomes of hospitalized patients were single-center studies and did not use a large diverse sample.

Impairment in kidney function and aging are predisposing factors for hypernatremia. Substantial knowledge gaps remain regarding prognostic implications of hypernatremia in hospitalized patients considering different levels of eGFR (16,17). Some studies have demonstrated that advanced CKD and lower eGFR have an apparent protective effect on hypernatremia-related mortality (18). However, controversies still exist over the outcomes of hypernatremia (17,18). The lack of population-based evidence supports the need to evaluate the relationship of hypernatremia to outcomes among hospitalized patients with various levels of kidney function.

To address the knowledge gaps regarding hypernatremia and its correlation with poor outcomes in hospitalized patients, we analyzed data on hospitalized patients from the Cerner Health Facts national database. Furthermore, we investigated the relationship between age and eGFR with outcomes among hospitalized patients.

Materials and Methods
We conducted an observational retrospective cohort study of patients hospitalized between 2000 and 2018 using the Cerner Health Facts database. The Institutional Review Board of the University of New Mexico approved this study protocol (no. 19-429). The requirement for informed consent was waived. This study was conducted in accordance with the principles of the Declaration of Helsinki.

We defined the index hospital admission as the first inpatient encounter during the study period for patients who met the following inclusion criteria: (1) age ≥18 years, and (2) first serum sodium concentration (Na) drawn within 24 hours of admission. The second inclusion criterion reduced the likelihood of the Na being affected by various treatments or iatrogenic causes after hospital admission. All laboratory results in Table 1 were taken within 24 hours of admission. The missing rate for laboratory results is reported in Supplemental Table 1.

Patient demographics, comorbidities, causes of admission, laboratory studies, and disposition status at hospital discharge were collected. The comorbidities were identified using the International Classification of Diseases, 9th and 10th editions, Clinical Modification (ICD-9 and 10 CM) codes. Laboratory tests were identified using Logical Observation Identifiers Names and Codes (LOINC) (19). The Quan-Charlson Comorbidity Index (Quan-CCI)—a comorbidity index adapted from the Charlson comorbidity index for administrative databases—was also calculated (20).

We corrected the Na by adding 1.6 mEq/L for each 100 mg/dl above 100 mg/dl of the concomitantly measured serum glucose levels (21–23). To calculate eGFR, we applied the CKD-EPI Equation (24). The primary outcomes were determined as in-hospital mortality, discharge disposition of hospitalized patients (hospice, nursing facility, or home), and length of stay. We further excluded patients with Na <135 mEq/L, those with missing eGFR and Na values, and those with discharge dispositions other than home, a hospice, or a nursing facility.

Statistical Analyses
Categorical variables were expressed as percentages, and subgroups were compared using chi-squared tests. Continuous variables were summarized as mean±SD or as medians and interquartile ranges if distributions were skewed. Patient characteristics in normonatremic (Na 135–145 mEq/L) and different hypernatremic (Na >145 mEq/L) groups (mild, moderate, severe) were compared using the Kruskal-Wallis test for continuous variables and the chi-squared test for categorical variables.

Interrelated associations between Na levels and multiple disposition outcomes were evaluated using multinomial logistic regression model analysis while accounting for the competing risks of in-hospital mortality and other dispositions. Discharge to home was used as the reference outcome. For a descriptive, graphical analysis, we used restricted cubic splines in the model to estimate probabilities for in-hospital mortality and discharge to a hospice or nursing facility across the continuous range of Na. For our primary analyses, we discretized Na into four categories: normonatremia: Na 135–145 mEq/L (reference category); mild hypernatremia: Na >145–150 mEq/L; moderate hypernatremia: Na >150–155 mEq/L; and severe hypernatremia: Na >155 mEq/L. Analysis models without and with covariates were fitted for age, sex, race/ethnicity, CKD, and Quan-CCI.

Potential effect modification of the relationship between eGFR and outcomes by Na was assessed by adding Na category×eGFR category interactions to models. We categorized eGFR levels into five different groups: eGFR ≥90 ml/min per 1.73 m² (reference category), eGFR 60–89 ml/min per 1.73 m², eGFR 30–59 ml/min per 1.73 m², eGFR 15–29 ml/min per 1.73 m², and eGFR <15 ml/min per 1.73 m². Sensitivity of eGFR models to race was assessed by removing race from the model.

Potential effect modification of the relationship between age and outcomes by Na was assessed by adding Na category×age category interactions to models. To evaluate interrelated associations between age and outcome of Na, we categorized age into five different groups: 18–45, 46–65 (reference category), 66–75, 76–89, and ≥90 years old. Custom linear contrasts were used to obtain odds ratios (OR) by subgroup. Sensitivity analysis of results to patient comorbidities was conducted by replacing selected covariates with Quan-CCI. Predicted values from models were obtained to visualize relationships between Na and outcomes.

Finally, we assessed the relationships between Na levels and length of hospitalization (days) among those who were discharged to home. The distribution was right skewed, so log-transformed days were used in linear models of length of stay adjusted for CKD and the Quan-CCI, taking an approach that follows our multinomial logistic regression analyses. We report regression coefficients from the models to summarize the magnitude of the effect on log-transformed days. Moreover, we tested for the differential effect of age and eGFR on these associations. All statistical analyses were performed using R v3.4 (The R Foundation for Statistical Computing, Vienna, Austria).
| Patient Characteristics | All Cohort, N=1,963,020 (100%) | Normonatremia, N=1,902,406 (97%) | Hypernatremia, N=60,614 (3%) | Standardized Mean Difference |
|-------------------------|--------------------------------|----------------------------------|-----------------------------|-----------------------------|
| **Age, yr**             | 58.2 (±19.2)                  | 57.9 (±19.2)                     | 65.5 (±18.7)                | 0.4                         |
| **BMI, kg/m²**          | 29.6 (±8.1)                   | 29.6 (±8.1)                      | 27.8 (±8.1)                 | 0.23                        |
| **Systolic BP, mm Hg**  | 137.8 (±26)                   | 137.8 (±25.9)                    | 136.7 (±29.7)               | 0.04                        |
| **Diastolic BP, mm Hg** | 78 (±15.8)                    | 78 (±15.8)                       | 76.6 (±17.6)                | 0.08                        |
| eGFR, ml/min per 1.73 m²| 81.2 (±30.2)                  | 81.7 (±30)                       | 65.9 (±32.2)                | 0.51                        |
| **Sex**                 |                                |                                  |                             |                             |
| Women                   | 1,036,709 (53)                | 1,005,506 (53)                   | 31,203 (52)                 | 0.03                        |
| **Race**                |                                |                                  |                             |                             |
| White                   | 1,508,639 (77)                | 1,465,674 (77)                   | 42,965 (71)                 |                             |
| Black                   | 283,213 (14)                  | 271,349 (14)                     | 11,864 (20)                 |                             |
| Native American         | 18,502 (0.9)                  | 17,412 (0.9)                     | 1092 (2)                    |                             |
| Asian                   | 31,399 (2)                    | 30,342 (2)                       | 1057 (2)                    |                             |
| Hispanic                | 35202 (2)                     | 34,173 (2)                       | 45 (0.1)                    |                             |
| Pacific Islander        | 3277 (0.2)                    | 3232 (0.2)                       | 456 (4)                     |                             |
| Other                   | 82,788 (4)                    | 80,224 (4)                       | 2564 (4)                    |                             |
| **Quan-CCI categories** |                                |                                  |                             |                             |
| 0                       | 716,464 (37)                  | 699,932 (37)                     | 16,532 (27)                 | 0.29                        |
| 1–2 (mild)              | 477,687 (24)                  | 462,726 (24)                     | 14,961 (25)                 |                             |
| 3–4 (moderate)          | 219,075 (11)                  | 209,590 (11)                     | 9485 (16)                   |                             |
| ≥5 (severe)             | 196,545 (10)                  | 186,407 (10)                     | 10,138 (17)                 |                             |
| Unknown                 | 353,249 (18)                  | 343,751 (18)                     | 9498 (16)                   |                             |
| Quan-CCI                | 1.8 (±2.3)                    | 1.7±2.3                          | 2.4±2.7                     | 0.28                        |
| **Comorbidities**       |                                |                                  |                             |                             |
| Hypertension            | 648,371 (33)                  | 627,375 (33)                     | 20,996 (35)                 | 0.07                        |
| Heart failure           | 167,581 (9)                   | 158,558 (8)                      | 9027 (15)                   | 0.22                        |
| Diabetes mellitus       | 336,193 (17)                  | 321,721 (17)                     | 14,472 (24)                 | 0.18                        |
| Peripheral vascular disease | 50,629 (3)               | 48,794 (3)                       | 1835 (3)                    | 0.03                        |
| Ischemic heart disease  | 339,847 (17)                  | 326,996 (17)                     | 12,851 (21)                 | 0.1                          |
| CKD                     | 113,837 (6)                   | 107,513 (6)                      | 6324 (10)                   | 0.19                        |
| ESKD                    | 21,559 (1)                    | 20,763 (1)                       | 796 (1)                     | 0.02                        |
| COPD                    | 275,385 (14)                  | 265,806 (14)                     | 9579 (16)                   | 0.04                        |
| Adrenal hyperactivity   | 750 (0)                       | 704 (0)                          | 46 (0.1)                    | 0.02                        |
| Hyperthyroidism         | 6475 (0.3)                    | 6219 (0.3)                       | 256 (0.4)                   | 0.02                        |
| Hypothyroidism          | 110,031 (6)                   | 106,415 (6)                      | 3616 (6)                    | 0.01                        |
| Liver disease           | 52,958 (3)                    | 50,561 (3)                       | 2397 (4)                    | 0.07                        |
| Depression              | 156,180 (8)                   | 150,750 (8)                      | 5430 (9)                    | 0.03                        |
| Dementia                | 29,178 (2)                    | 26,180 (1)                       | 2998 (5)                    | 0.22                        |
| Hypercoagulopathy       | 5226 (0.3)                    | 5108 (0.3)                       | 118 (0.2)                   | 0.02                        |
| **Leading diagnosis**   |                                |                                  |                             |                             |
| Head trauma             | 30,341 (2)                    | 28,591 (2)                       | 1750 (3)                    | 0.1                          |
| Ischemic stroke         | 50,237 (3)                    | 48,243 (3)                       | 1994 (3)                    | 0.04                        |
| Hemorrhagic stroke      | 8872 (0.5)                    | 8,293 (0.4)                      | 579 (1)                     | 0.07                        |
| Obstetrics/gynecologic conditions | 59,733 (3) | 59,528 (3) | 205 (0.3) | 0.24 |
| Pneumonia               | 113,544 (6)                   | 107,142 (6)                      | 6402 (11)                   | 0.19                        |
| Sepsis                  | 76,692 (4)                    | 70,196 (4)                       | 6496 (11)                   | 0.3                          |
| Central diabetes insipidus | 716 (0)                     | 568 (0)                          | 148 (0.2)                   | 0.06                        |
| Nephrogenic diabetes insipidus | 120 (0)       | 81 (0)                           | 39 (0.1)                    | 0.04                        |
| Urinary tract infection | 117,440 (6)                   | 109,994 (6)                      | 7446 (12)                   | 0.24                        |
| **Laboratory tests**    |                                |                                  |                             |                             |
| Serum albumin, g/dl     | 3.8 (±0.6)                    | 3.7 (±0.6)                       | 3.6 (±0.7)                  | 0.24                        |
| Serum creatinine, mg/dl | 1.1 (±1)                      | 1.1 (±1)                         | 1.4 (±1.2)                  | 0.28                        |
| Serum potassium, mEq/L  | 4 (±0.6)                      | 4 (±0.5)                         | 4.1 (±0.7)                  | 0.08                        |
| Glucose, mg/dl          | 134.8 (±73.3)                 | 133.5 (±70.5)                    | 172.7 (±124.4)              | 0.39                        |
| Hemoglobin A1C          | 7 (±2.1)                      | 7 (±2.1)                         | 7.4 (±2.4)                  | 0.15                        |
| CO₂, meq/L              | 25.3 (±3.9)                   | 25.3 (±3.8)                      | 24.8 (±5.7)                 | 0.12                        |
Table 1. (Continued)

| Patient Characteristics | All Cohort, N=1,963,020 (100%) | Normonatremia, N=1,902,406 (97%) | Hypernatremia, N=60,614 (3%) | Standardized Mean Difference |
|-------------------------|---------------------------------|-----------------------------------|-------------------------------|-----------------------------|
| O$_2$ saturation, %      | 96.3 (±6.3)                     | 96.3 (±6.2)                       | 95.5 (±8.3)                  | 0.11                        |
| Calcium, mg/dl           | 9.1 (±0.6)                      | 9.1 (±0.6)                        | 9.1 (±0.9)                   | 0.06                        |
| Phosphorus, mg/dl        | 3.5 (±1.2)                      | 3.5 (±1.1)                        | 3.8 (±1.7)                   | 0.2                         |
| Magnesium, mmol/L        | 2 (±0.4)                        | 2 (±0.4)                          | 2.1 (±0.5)                   | 0.29                        |
| Chloride, mmol/L         | 103.6 (±4.3)                    | 103.5 (±4.1)                      | 108.2 (±5.9)                 | 0.93                        |
| Serum osmolality, mOsm/L | 299 (±27.5)                     | 295.8 (±24.9)                     | 326.9 (±32.3)                | 1.08                        |
| Anion gap, mmol/L        | 10.8 (±4.1)                     | 10.7 (±4.2)                       | 13.6 (±5.6)                  | 0.61                        |
| Intact PTH, pg/ml        | 195.8 (±299.7)                  | 195.8 (±299.4)                    | 196.6 (±305.5)               | 0.003                       |
| Ferritin, ng/ml          | 228.5 (±359.6)                  | 226.1 (±357.5)                    | 293.4 (±404.8)               | 0.18                        |
| Iron saturation, %       | 21.9 (±22.3)                    | 21.9 (±22.3)                      | 21.8 (±20.9)                 | 0.003                       |
| Hemoglobin, g/dl         | 13 (±2.2)                       | 13 (±2.2)                         | 12.8 (±2.5)                  | 0.09                        |
| WBC, >10³/ml             | 10 (±4.7)                       | 10 (±4.6)                         | 11.2 (±6.2)                  | 0.22                        |
| Platelet count           | 233.4 (±83.8)                   | 233.7 (±83.5)                     | 225.9 (±92.4)                | 0.09                        |
| Serum uric acid, mmol/L  | 96.6 (±37.1)                    | 95.9 (±36.3)                      | 115.3 (±49.5)                | 0.45                        |
| BUN, mmol/L              | 18.8 (±13.7)                    | 18.5 (±13.2)                      | 28.7 (±22.7)                 | 0.55                        |
| AST, IU/L                | 45 (±94.3)                      | 42.4 (±92.2)                      | 62.7 (±142.7)                | 0.17                        |
| ALT, IU/L                | 39.7 (±81.8)                    | 39.3 (±80.8)                      | 50 (±107.6)                  | 0.11                        |
| Total bilirubin, μmol/L  | 0.7 (±0.9)                      | 0.7 (±0.9)                        | 0.7 (±0.8)                   | 0.04                        |
| Serum total protein, mg/dl| 6.9 (±0.8)                      | 6.9 (±0.8)                        | 6.8 (±1)                    | 0.12                        |

Data shown as mean (±SD) or n (%). Normonatremia: serum sodium (Na) 135–145 mEq/L; hypernatremia: Na >145 mEq/L. Na levels corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the concomitantly measured serum glucose levels. BMI, body mass index; Quan-CCI, Quan-Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; PTH, parathyroid hormone; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Results

A total of 3,896,382 patients met our inclusion criteria. The final cohort included 1,963,020 patients (Figure 1), of whom 60,614 (3%) had hypernatremia (Na >145 mEq/L) at hospital admission.

Hypernatremic patients had significantly lower eGFR and were older compared with normonatremic patients (both P<0.001). Patient characteristics are summarized in Table 1. We found statistically significant differences (P<0.001) for the comparison between hypernatremic and normonatremic patients for all patient characteristics. We also reported standardized mean differences. Some of the laboratory data in Table 1 had a high missing rate. Supplemental Table 1 details the missing rate. One reason for such a large percentage of missing laboratory values could be the time frame of blood test drawing (within 24 hours of admission). We did not include the laboratory tests taken after 24 hours of admission.

Frequency of outcomes by hypernatremia status, eGFR category, and age group are summarized in Supplemental Table 2. The incidence of in-hospital mortality was 12% among hypernatremic patients compared with 2% in normonatremic patients. The relative frequencies of discharge to a hospice in hypernatremic and normonatremic patients were 2% and 0.7%, respectively. The relative frequencies of discharge to a nursing facility in hypernatremic and normonatremic patients were 26% and 11%, respectively.

Serum Sodium and the Outcomes

The crude probability of in-hospital mortality corresponding to Na was lowest between 135 and 145 mEq/L and continued to increase above this range (Figure 2). The probability of discharge to a hospice demonstrated a similar pattern, albeit less profound. The estimated probability of discharge to a nursing facility at lower Na levels appeared to show an up-trending pattern but started to decrease at Na above 155 mEq/L. The probability of discharge to home increased to an Na between 135 and 145 mEq/L, then decreased above this range, and again started to increase slightly above 155 mEq/L. Discharge to a hospice showed a slight increase at Na above 150 mEq/L and then remained steady (Figure 2).

For the Na categories, in the adjusted multinomial logistic regression analysis, we found that the OR for in-hospital mortality significantly increased as Na increased relative to normonatremia interval (P<0.001). We observed similar trends for discharge to a hospice or nursing facility (Table 2).

There was a significant association between Na categories and length of hospitalization (P<0.001). These overall relationships are shown in Table 4. For those discharged to their homes, median length of stay was 2.94 days. Length of stay was shortest for normonatremia.

eGFR and the Outcomes

The main test for interaction between eGFR levels and Na categories demonstrated a significant association between these two factors and in-hospital mortality (P<0.001). Generally, crude ORs of in-hospital mortality increased as Na increased relative to the 135–145 mEq/L interval and as eGFR decreased below 90 ml/min per 1.73 m². This was also true for discharge to a hospice or nursing facility (Figure 3, Table 2).

The adjusted model showed that the ORs of in-hospital mortality significantly increased as Na rose above 145 mEq/L and eGFR decreased below 90 ml/min per 1.73 m².
Patients meeting inclusion criteria, 
\( n = 3,896,382 \)

Disposition missing or other than at Home, Hospice, Nursing or Hospital Mortality, 
\( n = 1,388,727 \)

Missing or Serum [Na] levels <135 mEq/L, 
\( n = 491,860 \)

Missing eGFR levels, 
\( n = 52,775 \)

Admission included\(^a\) \( n = 1,963,020 \)

---

**Figure 1.** Flow chart of the sample selection process. \(^a\)The final cohort available for analysis. Serum sodium levels were corrected by adding 1.6 mEq/L for each 100 mg/dl above 100 mg/dl of the concomitantly measured serum glucose levels.

---

**Figure 2.** Restricted cubic splines of the crude probability of in-hospital mortality, discharge to a hospice, discharge to home, and discharge to a nursing facility as a function of serum sodium levels at hospital admission. These estimated probabilities were derived from a multinomial logistic regression model. Serum sodium levels were corrected by adding 1.6 mEq/L for each 100 mg/dl above 100 mg/dl of the concomitantly measured serum glucose levels.
compared with the reference Na interval and eGFR >90 ml/min per 1.73 m² (P<0.001). Different trends were observed for each Na category (Table 2, Figure 3).

In the unadjusted model, discharge to a hospice showed the same trend as for in-hospital mortality. The highest ORs in normonatremia and mild hypernatremia were observed with an eGFR of 15–29 and in moderate and severe hypernatremia with an eGFR <15 ml/min per 1.73 m². In all Na categories, the lowest ORs of discharge to a hospice were observed with an eGFR ≥90 ml/min per 1.73 m² (Figure 3). Adjusted model showed different patterns in each Na category (Figure 3, Table 2).

With regard to discharge to a nursing facility, the unadjusted model showed that in normonatremia and mild and moderate hypernatremia, the highest ORs were observed with an eGFR of 15–29 ml/min per 1.73 m², whereas the lowest ORs were observed with an eGFR ≥90 ml/min per 1.73 m² (Figure 3).

Length of stay showed an up-trending pattern as function of eGFR in all Na categories, with the two exceptions of patients with an eGFR of 60–89 ml/min per 1.73 m² in normonatremia and mild hypernatremia, who had the shortest length of stay. For moderate and severe hypernatremia, the shortest length of stay was observed for eGFR ≥90 ml/min per 1.73 m². The longest length of stay was observed for those with an eGFR <15 ml/min per 1.73 m² in all Na categories (Figure 4, Table 4).

The sensitivity analysis was performed using the eGFR equation without race as a covariate. The inferences did not substantially change after removing race from our eGFR model (Figure 5).

### Age and the Outcomes

In all Na categories, we found a significant association between age and outcomes (all P<0.001). The crude results showed that older age groups had higher ORs of in-hospital mortality and discharge to a hospice or nursing facility in all Na categories (Figure 6). In the adjusted model, in each Na category, the relationship between age

| Table 2. Relationships between serum sodium levels stratified by eGFR levels and outcomes |
|---------------------------------|---------------------------------|---------------------------------|
| Natremia Status* at Hospital Admission | In-Hospital Mortality | Discharge to a Hospice | Discharge to a Nursing Facility |
|---------------------------------|-----------------|-----------------|-----------------|
| Normonatremia | Adjusted $^b$ Odds Ratio | Adjusted $^b$ Odds Ratio | Adjusted $^b$ Odds Ratio |
| | (95% Confidence Interval) | (95% Confidence Interval) | (95% Confidence Interval) |
| Hypernatremia | | | |
| Mild | 4.8 (4.6 to 4.9) | 2.1 (1.9 to 2.3) | 2.1 (2 to 2.1) |
| Moderate | 22.6 (20.9 to 24.4) | 10.41 (9 to 12) | 6.97 (6.5 to 7.5) |
| Severe | 34.4 (30.6 to 38.7) | 21.1 (17.5 to 25.5) | 12.2 (11 to 13.6) |
| eGFR level, ml/min per 1.73 m² | | | |
| Normonatremia | | | |
| <15 | 5.4 (5.1 to 5.6) | 0.8 (0.7 to 0.9) | 1.4 (1.3 to 1.4) |
| 15–29 | 5.5 (5.3 to 5.8) | 1 (0.9 to 1) | 1.4 (1.3 to 1.4) |
| 30–59 | 2.3 (2.2 to 2.4) | 0.5 (0.5 to 0.5) | 1 (1 to 1) |
| 60–89 | 1.5 (1.4 to 1.5) | 0.6 (0.5 to 0.6) | 0.9 (0.9 to 1) |
| ≥90 | 1 | 1 | 1 |
| Mild hypernatremia | | | |
| <15 | 14 (12.4 to 16) | 0.1 (0.1 to 0.3) | 2.7 (1.9 to 2.4) |
| 15–29 | 19.2 (17.6 to 21.1) | 0.4 (0.3 to 0.5) | 4 (3.7 to 4.3) |
| 30–59 | 11.9 (11.2 to 12.7) | 2 (1.7 to 2.1) | 2.5 (2.4 to 2.6) |
| 60–89 | 6 (5.5 to 6.4) | 1.7 (1.5 to 1.9) | 1.6 (1.6 to 1.7) |
| ≥90 | 8.1 (7.4 to 8.7) | 1.6 (1.3 to 2) | 2.2 (2 to 2.3) |
| Moderate hypernatremia | | | |
| <15 | 54.6 (42.5 to 70.2) | 0.17 (0 to 1.9) | 6.6 (5.2 to 8.4) |
| 15–29 | 69.3 (55.8 to 86) | 3.91 (2.3 to 6.6) | 16.5 (13.6 to 20.1) |
| 30–59 | 22 (19 to 25.4) | 5 (3.9 to 6.4) | 5.4 (4.8 to 6.1) |
| 60–89 | 36.6 (30.6 to 43.9) | 36.4 (29.5 to 44.8) | 11.6 (10 to 13.5) |
| ≥90 | 15.5 (12.5 to 19.3) | 0 (NA) | 4 (3.3 to 4.8) |
| Severe hypernatremia | | | |
| <15 | 656.5 (328.7 to 1311.1) | 4.2 (0.5 to 34.2) | 124.3 (62.8 to 246.6) |
| 15–29 | 849 (67.2 to 107.2) | 9.1 (6.1 to 13.7) | 10.7 (8.5 to 13.4) |
| 30–59 | 89.6 (73.4 to 109.3) | 12.2 (8.5 to 17.4) | 15.2 (12.6 to 18.4) |
| 60–89 | 300.5 (215.1 to 419.9) | 52.2 (32.2 to 84.7) | 33.6 (23.9 to 47.3) |
| ≥90 | 30 (19.9 to 45.4) | 34.6 (19.6 to 61) | 10 (7 to 14.2) |

Normonatremia: Na >135–145 mEq/L; hypernatremia: Na >145 mEq/L (mild hypernatremia: Na >145–150 mEq/L; moderate hypernatremia: Na >150–155 mEq/L; severe hypernatremia: Na >155 mEq/L). Na, serum sodium level; OR, odds ratio.

*Na levels corrected by adding 1.6 mEq/L for each 100 mg/dl above 100 mg/dl of the concomitantly measured serum glucose levels.

$^b$The adjusted ORs were derived from a multinomial logistic regression model adjusted for age, sex, race, CKD, and the Quan-CCI (all P<0.001).
group and outcomes was largely similar to those in the crude models, with an increased risk of mortality and discharge to a hospice or nursing facility with older age (Figure 6, Table 3).

Across all Na categories, older age was associated with greater length of stay (Figure 4, Table 4).

Discussion
In this cohort study composed from a data warehouse for a large number of hospitals, we found that 3% of hospitalized patients had hypernatremia (Na >145 mEq/L). We demonstrated that in-hospital mortality was associated with higher levels of hypernatremia. The observation that...
hypernatremia was associated with a higher mortality rate (12%) was found to be independent of observed chronic disease. We also noticed a significant association between hypernatremia and increased odds of discharge to a hospice or nursing facility.

This report confirms previous observations relating hypernatremia to mortality in a large and diverse sample and hospitalized patients and extends previous research by examining discharge disposition. Tsipotis et al.'s (1) cohort study of 19,072 unselected hospitalized adults to investigate the crude relationship between clinical outcomes and community-acquired hypernatremia, defined as Na > 142 mEq/L, demonstrating a relationship between hypernatremia and mortality among these patients. In addition, Tsipotis et al.'s study revealed a decrement in ORs of in-hospital mortality for Na > 157 mEq/L in both the unadjusted and adjusted models (1). Our findings in terms of increment of in-hospital mortality along with the increase in the severity of hypernatremia are similar to the findings by Jin Jung et al. (3), who studied 79,998 patients, including 180 patients with hypernatremia, admitted to an urban tertiary care hospital in Korea. However, our conclusion is in contrast with the findings of Bataille et al. (25), who did not find a statistical relationship between the level of hypernatremia and mortality. In
line with our results, previous studies by Hu et al. (13,26) in China and Funk et al. (14) in Austria demonstrated that there are independent associations between hypernatremia and the risk of in-hospital mortality, even after adjusting for potential confounding factors.

The results of this report revealed that eGFR was significantly lower in hypernatremic patients compared with normonatremic patients. With regard to the different levels of hypernatremia stratified by eGFR levels, the general pattern showed that by increasing Na and decreasing eGFR level, the risk of outcomes increased. Tsipotis et al. (1) showed that the highest ORs of in-hospital mortality in patients with hypernatremia on admission belonged to eGFR 30–59 ml/min per 1.73 m². Han et al. (27) investigated

---

Figure 5. | Plot of the relative risk ratios (95% CI) for in-hospital mortality and discharge to a hospice or nursing facility associated with different intervals of serum sodium levels (mEq/L) at hospital admission stratified by eGFR levels with developing race/ethnicity in the model. (A) Before removing race from model. (B) After removing race from model. The sensitivity analyses were performed using the eGFR equation without a race covariate.
associations between Na and CKD and observed that hypernatremia in patients with CKD in the outpatient setting were short- and long-term risk factors for mortality. Chiu et al. (28) reported no significant association with hypernatremia and mortality in an outpatient population with CKD. Sun et al. also found that the stage of CKD did not appear to affect the mortality associated with hypernatremia (29). In contrast, Kovesdy et al. (18) demonstrated that more advanced CKD displayed a relatively lower mortality associated with hypernatremia compared with patients with less severe stages of CKD. These differences can result from the nature of our inpatient population, who suffer from more acute conditions.

Patients with hypernatremia were older than normonatremic patients (65.51 ± 18.70 years and 57.93 ± 19.18 years, respectively; \( P < 0.001 \)). The results of our analyses generally revealed an up-trending pattern of ORs for all outcomes in higher Na and older age groups. In accordance with these findings, the odds ratio for hospital mortality increased as Na levels increased, with the highest OR observed for patients with serum Na > 155 mmol/L (unadjusted OR = 3.95; adjusted OR = 4.20).

Figure 5. (Continued)
with other studies (30–32), our study demonstrated that the odds of in-hospital mortality in all Na groups increased with aging. This can be attributed to the fact that elderly patients with hypernatremia present with fewer symptoms of hypernatremia compared with younger patients. A delay in diagnosis and treatment of hypernatremia can carry higher rates of mortality and poorer outcomes. Moreover, age-related impairment in organ function, decreased thirst drive, impaired urinary concentrating ability, reduced total body water, chronic illnesses, and disabilities predispose older adults to dehydration and hypernatremia (30). Our results also demonstrated that older patients with higher Na had greater ORs of discharge to a nursing facility.

Our study has several strengths. First, to the best of our knowledge, the association between hypernatremia and its outcomes (i.e., in-hospital mortality and discharge dispositions) has not been studied systematically at a large population level. Additionally, our study addressed a key gap in knowledge because we investigated the relationship between different levels of hypernatremia and selected outcomes through stratifying by eGFR level and age group in a large diverse population. Our study also has some

Figure 6. | Plot of the relative risk ratios (95% CI) for in-hospital mortality and discharge to a hospice or nursing facility associated with different intervals of serum sodium levels (mEq/L) at hospital admission stratified by age groups.
Assessment. However, this study included the identi-
ifications of kidney function (based on eGFR). Nevertheless, these
limitations should not undermine the importance of the
bility. First, we were unable to include a disease
considering the level of kidney function and age. Duration of
neous about hypernatremia and emphasizes the need for
in-hospital mortality and discharge to a hospice or
ening authors have nothing to disclose.
Nephrology, NKF, and the Renal Research Institute related to lec-
ner for AKI in this report, and this is a limitation. However, the
aim of our study was to investigate the relationships
between hypernatremia and outcomes considering the level of
kidy function (based on eGFR). Nevertheless, these
limitations should not undermine the importance of the
finding that hypernatremia, regardless of the cause, is sig-
nificantly associated with increased in-hospital mortality.
Hypernatremia is relatively common among hospitalized
patients, and regardless of the cause, it is significantly
related to mortality and discharge to a nursing facility or
hospice. Our study underscores the need for more aware-
ness about hypernatremia and emphasizes the need for
addressing water depletion among patients presenting to
hospital with hypernatremia. We found that all levels of
hypernatremia independently increased the odds of
in-hospital mortality and discharge to a hospice or nursing
facility. The prognosis for hypernatremic patients may
improve if hypernatremia is corrected properly and in a
timely manner. Further studies are needed to evaluate and
develop the best treatment and management of hypernatremia
in order to decrease the rate of adverse outcomes con-
sidering the level of kidney function and age. Duration of
hypernatremia and its effect on poor outcomes is another
issue that merits further study.

Table 3. Relationships between serum sodium levels, stratified by age, and outcomes

| Natriemia Statusa at Hospital Admission | Age Group, yr | In-Hospital Mortality Adjusted8 Odds Ratio (95% Confidence Interval) | Discharge to a Hospice Adjusted8 Odds Ratio (95% Confidence Interval) | Discharge to a Nursing Facility Adjusted8 Odds Ratio (95% Confidence Interval) |
|----------------------------------------|--------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Normonatremia                           | 18–45        | 0.4 (0.4 to 0.4)                                | 0 (N/A)                                         | 0.2 (0.2 to 0.2)                                  |
|                                        | 46–65        | 1                                               | 1                                               | 1                                               |
|                                        | 66–75        | 1.8 (1.76 to 1.9)                               | 2.4 (2.3 to 2.6)                                | 2.9 (2.8 to 2.9)                                  |
|                                        | 76–89        | 4 (3.9 to 4.1)                                  | 5.9 (5.6 to 6.3)                                | 8.1 (8 to 8.2)                                   |
| ≥90                                    |              | 11 (10.6 to 11.5)                              | 21.8 (20.5 to 23.3)                             | 21.7 (21.2 to 22.1)                              |
| Mild hypernatremia                     | 18–45        | 7.1 (6.5 to 7.8)                                | 1.1 (0.7 to 1.7)                                | 0.8 (0.7 to 0.9)                                 |
|                                        | 46–65        | 5.7 (5.4 to 6.1)                                | 2 (1.6 to 2.4)                                  | 2.1 (2 to 2.2)                                   |
|                                        | 66–75        | 7.7 (7.2 to 8.3)                                | 3.4 (2.8 to 4.2)                                | 5.7 (5.4 to 6)                                   |
|                                        | 76–89        | 14.9 (14.1 to 15.8)                             | 10.3 (9 to 11.7)                                | 15 (14.4 to 15.5)                                |
| ≥90                                    |              | 48.3 (43.5 to 53.6)                             | 62.8 (53.7 to 73.4)                             | 36.2 (33.3 to 39.3)                              |
| Moderate hypernatremia                | 18–45        | 14.8 (12 to 18.2)                               | 0.1 (0 to 14.1)                                 | 0.8 (0.5 to 1.2)                                 |
|                                        | 46–65        | 16.1 (13.8 to 18.8)                             | 7.2 (4.7 to 11.2)                               | 7 (6.1 to 8)                                     |
|                                        | 66–75        | 66.7 (55.8 to 79.8)                             | 16.9 (10.1 to 28.4)                             | 29.5 (25.1 to 34.7)                              |
|                                        | 76–89        | 96.2 (83.3 to 111.1)                            | 68.3 (53.4 to 87.4)                             | 61.3 (54.1 to 69.5)                              |
| ≥90                                    |              | 57.3 (45.7 to 71.7)                             | 59.3 (41.7 to 84.5)                             | 36.5 (30.3 to 43.9)                              |
| Severe hypernatremia                  | 18–45        | 3.7 (1.9 to 7.3)                                | 10.2 (4.2 to 24.6)                              | 0.3 (0.1 to 1)                                   |
|                                        | 46–65        | 16.2 (12.3 to 21.4)                             | 3.7 (1.3 to 10.8)                               | 12.7 (9.9 to 14.9)                               |
|                                        | 66–75        | 18.5 (14.2 to 24.2)                             | 12.3 (6.8 to 22.3)                              | 11.7 (9.7 to 14.7)                               |
|                                        | 76–89        | 98.4 (79.4 to 122)                              | 194.8 (150 to 252.9)                            | 99.6 (83.1 to 119.3)                             |
| ≥90                                    |              | 181.7 (130.6 to 252.7)                          | 87.5 (49.1 to 156.1)                            | 94 (69.4 to 127.3)                               |

Normonatremia: Na >135–145 mEq/L; hypernatremia: Na >145 mEq/L; moderate hypernatremia: Na >150–155 mEq/L; severe hypernatremia: Na >155 mEq/L. CI, confidence interval; Na, serum sodium level; OR, odds ratio.

aNa levels corrected by adding 1.6 mEq/L for each 100 mg/dl above 100 mg/dl of the concomitantly measured serum glucose levels.

bThe adjusted ORs were derived from a multinomial logistic regression model adjusted for age, sex, race, CKD, and the Quan-CCI (all P<0.001).

Disclosures

M.L. Unruh reports consultancy for Cara Therapeutics to chair of Data Monitoring Committee; a consulting agreement between Cara and the University of New Mexico; research funding from Dialysis Clinic, Inc.; and honoraria from the American Society of Nephrology, NKF, and the Renal Research Institute related to lectures. M.-E. Roumelliotis reports participating in Dialysis Clinic, Inc., quality meetings and receiving financial support. All remaining authors have nothing to disclose.
Table 4. Relationships between serum sodium levels at hospital admission and length of hospitalization among those discharged to home (stratified by eGFR/age)

| Natremia Statusa at Hospital Admission | Length of Stay among those Discharged to Home (N=1,664,500) |
|---------------------------------------|-----------------------------------------------------------|
|                                       | Median, Interquartile Range | Coefficient and 95% Confidence Interval |
| Normonatremia                         |                            |                                         |
|                                       |                            |                                         |
| Hypernatremia                         |                            |                                         |
| Mild                                   | 2.9 (1.9–4.6)              | Reference                               |
| Moderate                               | 4.1 (2.7–7.0)              | 0.3 (0.2 to 0.3)                        |
| Severe                                 | 4.7 (3–7.7)                | 0.4 (0.3 to 0.4)                        |
| Hypernatremia, per 1.73 m² of serum glucose level corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the concomitantly measured serum glucose levels.

Length of Stay among those Discharged to Home (N=1,664,500)

| Natremia Statusa at Hospital Admission | Median, Interquartile Range | Coefficient and 95% Confidence Interval |
|---------------------------------------|-----------------------------|----------------------------------------|
| Normonatremia                         |                            |                                         |
| Mild                                   | 4.2 (2.6–6.5)              | 0.2 (0.1 to 0.3)                       |
| Moderate                               | 3.5 (2.2–5.6)              | 0.1 (0.1 to 0.1)                       |
| Severe                                 | 3.0 (2–4.9)                | 0.05 (0.04 to 0.05)                    |
| Hypernatremia                          |                            |                                         |
| Mild                                   | 2.9 (1.9–4.4)              | –0.01 (–0.02 to 0.01)                  |
| Moderate                               | 2.9 (1.9–4.4)              | Reference                               |
| Severe                                 | 4.3 (2.8–6.9)              | 0.3 (0.2 to 0.3)                       |
| Hypernatremia, per 1.73 m² of serum glucose level corrected by adding 1.6 mEq/L for each 100 mg/dL above 100 mg/dL of the concomitantly measured serum glucose levels.

Age group, yr

| Natremia Statusa at Hospital Admission | Median, Interquartile Range | Coefficient and 95% Confidence Interval |
|---------------------------------------|-----------------------------|----------------------------------------|
| Normonatremia                         |                            |                                         |
| 18–45                                 | 2.9 (1.9–4.4)              | 0 (N/A)                                 |
| 46–65                                 | 3.0 (1.9–4.7)              | Reference                               |
| 66–75                                 | 3.0 (1.9–4.7)              | 0 (N/A)                                 |
| 76–89                                 | 3.2 (2–4.7)                | Reference                               |
| Mild hypernatremia                    |                            |                                         |
| 18–45                                 | 3.1 (2.5–3.1)              | 0.1 (0.09 to 0.1)                      |
| 46–65                                 | 3.4 (2.1–5.7)              | 0.1 (0.1 to 0.1)                       |
| 66–75                                 | 3.3 (2.1–5.4)              | 0.1 (0.1 to 0.1)                       |
| 76–89                                 | 3.3 (2.1–5.3)              | 0.1 (0.1 to 0.1)                       |
| Severe hypernatremia                  |                            |                                         |
| 18–45                                 | 3.8 (2.4–6.1)              | 0.2 (0.2 to 0.3)                       |
| 46–65                                 | 4.2 (2.7–7.2)              | 0.3 (0.2 to 0.3)                       |
| 66–75                                 | 4.4 (2.5–7.9)              | 0.3 (0.2 to 0.4)                       |
| 76–89                                 | 4.7 (3.6–6.9)              | 0.3 (0.2 to 0.4)                       |
| ≥90                                   | 3.9 (2.8–6.1)              | 0.2 (0.1 to 0.4)                       |
| Severe hypernatremia                  |                            |                                         |
| 18–45                                 | 4.3 (3.2–7.8)              | 0.4 (0.2 to 0.5)                       |
| 46–65                                 | 4.7 (2.8–7.9)              | 0.4 (0.2 to 0.5)                       |
| 66–75                                 | 4.4 (2.9–7.8)              | 0.3 (0.2 to 0.5)                       |
| 76–89                                 | 4.8 (3.4–7.1)              | 0.4 (0.2 to 0.5)                       |
| ≥90                                   | 5.8 (3–6.7)                | 0.3 (0.1 to 0.5)                       |

Table 4. Relationships between serum sodium levels at hospital admission and length of hospitalization among those discharged to home (stratified by eGFR/age)

| Natremia Statusa at Hospital Admission | Length of Stay among those Discharged to Home (N=1,664,500) |
|---------------------------------------|-----------------------------------------------------------|
| Normonatremia                         |                            |                                         |
| Mild                                   | 4.2 (2.6–6.5)              | 0.2 (0.1 to 0.3)                       |
| Moderate                               | 3.5 (2.2–5.6)              | 0.1 (0.1 to 0.1)                       |
| Severe                                 | 3.0 (2–4.9)                | 0.05 (0.04 to 0.05)                    |
| Hypernatremia                          |                            |                                         |
| Mild                                   | 2.9 (1.9–4.4)              | –0.01 (–0.02 to 0.01)                  |
| Moderate                               | 2.9 (1.9–4.4)              | Reference                               |
| Severe                                 | 4.3 (2.8–6.9)              | 0.3 (0.2 to 0.3)                       |

Table 4. Relationships between serum sodium levels at hospital admission and length of hospitalization among those discharged to home (stratified by eGFR/age)

| Natremia Statusa at Hospital Admission | Length of Stay among those Discharged to Home (N=1,664,500) |
|---------------------------------------|-----------------------------------------------------------|
| Normonatremia                         |                            |                                         |
| Mild                                   | 4.2 (2.6–6.5)              | 0.2 (0.1 to 0.3)                       |
| Moderate                               | 3.5 (2.2–5.6)              | 0.1 (0.1 to 0.1)                       |
| Severe                                 | 3.0 (2–4.9)                | 0.05 (0.04 to 0.05)                    |
| Hypernatremia                          |                            |                                         |
| Mild                                   | 2.9 (1.9–4.4)              | –0.01 (–0.02 to 0.01)                  |
| Moderate                               | 2.9 (1.9–4.4)              | Reference                               |
| Severe                                 | 4.3 (2.8–6.9)              | 0.3 (0.2 to 0.3)                       |

References
1. Tsipotis E, Price LL, Jaber BL, Madias NE: Hospital-associated hypernatremia spectrum and clinical outcomes in an unselected cohort. *Am J Med* 131: 72-82.e1, 2018.
2. Lombardi G, Ferraro PA, Calvaruso L, Naticchia A, D’Alonzo S, Cambaro G: Sodium fluctuations and mortality in a general hospitalized population. *Kidney Blood Press Res* 44: 604–614, 2019.
3. Jung WJ, Lee HJ, Park S, Lee SN, Kang HR, Jeon JS, Noh H, Han DC, Kwon SH: Severity of community acquired hypernatremia is an independent predictor of mortality. *Intern Emerg Med* 12: 935–940, 2017 28474207.
4. Thongprayoon C, Cheungpasitporn W, Yap JQ, Qian Q: Increased mortality risk associated with serum sodium variations and borderline hypo- and hypernatremia in hospitalized adults. *Nephrol Dial Transplant* 35: 1746–1752, 2020 31219584.
5. Akirov A, Diker-Cohen T, Steinmetz T, Amitai O, Shimon I: Sodium levels on admission are associated with mortality risk in hospitalized patients. *Eu J Int Med* 46: 25–29, 2017.
6. Girardreau Y, Jannot A-S, Chatellier G, Saint-Jean O: Association between borderline dysnatremia and mortality insight into a new data mining approach. *BMC Med Inform Decis Mak* 17: 152, 2017.
7. Lianis G, Filippatos TD, Elisaf MS: Evaluation and treatment of hypernatremia: A practical guide for physicians. *Postgrad Med* 128: 299–306, 2016 26813151.
8. Imaizumi T, Nakatoki M, Fujita Y, Nomura R, Watanabe K, Maekawa M, Yamakawa T, Katsuno T, Maruyama S: The association between intensive care unit-acquired hypernatremia and mortality in critically ill patients with cerebrovascular diseases: A single-centre cohort study in Japan. *BMJ Open* 7: e016248, 2017 28821524.
9. Salahudeen AK, Doshi SM, Shah P: The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center. *Support Care Cancer*: 21: 1871–1878, 2013.
10. Darmon M, Pichon M, Schwebel C, Ruckly S, Adrie C, Haouache H, Azoulay E, Bouadma L, Clech C, Garrouste-Orgeas M, Souweine B, Goldgraber D, Khalil H, Argaud L, Dumenil S, Jamali S, Allaouchiche B, Zeni F, Timsit J-F.
Influence of early dysnatremia correction on survival of critically ill patients. *Shock* 41: 394–399, 2014 24667611

11. Lopes IF, Dezelée S, Brau D, Steichen O: Prevalence, risk factors and prognosis of hypernatraemia during hospitalisation in internal medicine. *Neth J Med* 73: 448–454, 2015

12. Ceccconi M, Hochreiter H, Chew M, Grocott M, Hoefl A, Hoste A, Jammer I, Posch M, Metnitz P, Pelosi P, Moreno R, Pearse RM, Vincent JL, Rhodes A: Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery. *Br J Anaes* 116: 63–69, 2016

13. Hu J, Wang Y, Geng X, Chen R, Zhang P, Lin J, Teng J, Zhang X, Ding X: Dysnatremia is an independent indicator of mortality in hospitalized patients. *Med Sci Monit* 23: 2408–2425, 2017 28528344

14. Funk G-C, Lindner G, Druml W, Metnitz B, Bauer P, Metnitz PGH: Incidence and prognosis of dysnatremias present on ICU admission. *Intensive Care Med* 36: 304–311, 2010

15. Lianis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ: Electrolyte disorders in community subjects: Prevalence and risk factors. *Am J Med* 126: 256–263, 2013

16. Khan S, Floris M, Pani A, Rosner MH: Sodium and volume disorders in advanced chronic kidney disease. *Adv Chronic Kidney Dis* 23: 240–246, 2016 27324677

17. Kovesdy CP: Significance of hypo- AND hypernatremia in chronic kidney disease. *Nephrol Dial Transplant* 27: 891–898, 2012 22379183

18. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, Kalantar-Zadeh K: Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. *Circulation* 125: 677–684, 2012

19. Huff SM, Rocha RA, McDonald CJ, De Moor GJ, Fiers T, Bidgood WD, Forrey AW, Francis WG, Tracy WR, Leavelle D, Stallinger F, Griffin B, Maloney P, Leland D, Charles L, Hutchins K, Baenninger J: Development of the logical observation identifier names and codes (LOINC) vocabulary. *J Am Med Inform Assoc* 5: 276–292, 1998 9609498

20. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J-M, Sundararajan V: Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 173: 676–682, 2011 21330339

21. Katz MA: Hyperglycemia-induced hyponatremia—calculation of expected serum sodium depression. *N Engl J Med* 289: 843–844, 1973 4763428

22. Hillier TA, Abbott RD, Barrett EF: Hyponatremia: evaluating the correction factor for hyperglycemia. *Am J Med* 106: 399–403, 1999

23. Al Mawed S, Pankratz VS, Chong K, Sandoval M, Roumelioti M-E, Unruh M: Low serum sodium levels at hospital admission: Outcomes among 2.3 million hospitalized patients. *Plos ONE* 13: e0194379, 2018

24. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150: 604, 2009

25. Bataille S, Baralla C, Torro D, Buffat C, Berland Y, Alazia M, Loundou A, Michelet P, Vacher-Coponat H: Undercorrection of hypernatremia is frequent and associated with mortality. *BMC Nephrol* 15: 2014

26. Hu B, Han Q, Mengke N, He K, Zhang Y, Nie Z, Zeng H: Prognostic value of ICU-acquired hypernatremia in patients with neurological dysfunction. *Medicine (Baltimore)* 95: e3840, 2016 27583842

27. Han S-W, Tilea A, Gillespie BW, Finkelstein FO, Kiser MA, Eisele G, Kotanko P, Levin N, Saran R: Serum sodium levels and patient outcomes in an ambulatory clinic-based chronic kidney disease cohort. *Am J Nephrol* 41: 200–209, 2015

28. Chiu DYY, Kalra PA, Sinha S, Green D: Association of serum sodium levels with all-cause and cardiovascular mortality in chronic kidney disease: Results from a prospective observational study. *Nephrology* 21: 476–482, 2016

29. Sun L, Hou Y, Xiao Q, Du Y: Association of serum sodium and risk of all-cause mortality in patients with chronic kidney disease: A meta-analysis and systematic review. *Sci Rep* 7: 15949, 2017

30. Turgutalp K, Ozhan O, Gok Oguz E, Yilmaz A, Horoz M, Helvacı I, Kiykim A: Community-acquired hypernatremia in elderly and very elderly patients admitted to the hospital: Clinical characteristics and outcomes. *Med Sci Monit* 18: CR729–CR734, 2012

31. Snyder NA, Feigal DW, Ariei AI: Hypernatremia in elderly patients. A heterogeneous, morbid, and iatrogenic entity. *Ann Intern Med* 107: 309–319, 1987 3619220

32. Grangeon-Chapon C, Dodói M, Ensaïl VT, Favre G: Osmotic stress and mortality in elderly patients with kidney failure: A retrospective study. *Clin Interv Aging* 14: 225–229, 2019

Received: January 20, 2022 Accepted: April 18, 2022

See related editorial, “Outcomes Associated with Hypernatremia at Admission in Hospitalized Persons,” on pages 1122–1123.